Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth.

Miyake M, Furuya H, Onishi S, Hokutan K, Anai S, Chan O, Shi S, Fujimoto K, Goodison S, Cai W, Rosser CJ.

Theranostics. 2019 Jan 25;9(3):853-867. doi: 10.7150/thno.29553. eCollection 2019.

2.

Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer.

Masuda N, Ogawa O, Park M, Liu AY, Goodison S, Dai Y, Kozai L, Furuya H, Lotan Y, Rosser CJ, Kobayashi T.

Oncotarget. 2018 Jan 3;9(6):7101-7111. doi: 10.18632/oncotarget.23872. eCollection 2018 Jan 23.

3.

Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model.

Shimizu Y, Furuya H, Tamashiro PM, Iino K, Chan OTM, Goodison S, Pagano I, Hokutan K, Peres R, Loo LWM, Hernandez B, Naing A, Chong CDK, Rosser CJ, Kawamori T.

Carcinogenesis. 2018 Jan 12;39(1):47-55. doi: 10.1093/carcin/bgx097.

4.

Prognostic cancer gene signatures share common regulatory motifs.

Wang Y, Goodison S, Li X, Hu H.

Sci Rep. 2017 Jul 6;7(1):4750. doi: 10.1038/s41598-017-05035-3.

5.

Computational approach for deriving cancer progression roadmaps from static sample data.

Sun Y, Yao J, Yang L, Chen R, Nowak NJ, Goodison S.

Nucleic Acids Res. 2017 May 19;45(9):e69. doi: 10.1093/nar/gkx003.

6.

Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells.

Sankpal UT, Goodison S, Jones-Pauley M, Hurtado M, Zhang F, Basha R.

Oncotarget. 2017 Feb 28;8(9):14593-14603. doi: 10.18632/oncotarget.14651.

7.

A microRNA biomarker panel for the non-invasive detection of bladder cancer.

Urquidi V, Netherton M, Gomes-Giacoia E, Serie DJ, Eckel-Passow J, Rosser CJ, Goodison S.

Oncotarget. 2016 Dec 27;7(52):86290-86299. doi: 10.18632/oncotarget.13382.

8.

Urinary mRNA biomarker panel for the detection of urothelial carcinoma.

Urquidi V, Netherton M, Gomes-Giacoia E, Serie D, Eckel-Passow J, Rosser CJ, Goodison S.

Oncotarget. 2016 Jun 21;7(25):38731-38740. doi: 10.18632/oncotarget.9587.

9.

A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort.

Goodison S, Ogawa O, Matsui Y, Kobayashi T, Miyake M, Ohnishi S, Fujimoto K, Dai Y, Shimizu Y, Tsukikawa K, Furuya H, Rosser CJ.

J Transl Med. 2016 Oct 7;14(1):287.

10.

A Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer.

Huang S, Kou L, Furuya H, Yu C, Goodison S, Kattan MW, Garmire L, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1361-6. doi: 10.1158/1055-9965.EPI-16-0260. Epub 2016 Jul 6.

11.

A multiplex immunoassay for the non-invasive detection of bladder cancer.

Shimizu Y, Furuya H, Bryant Greenwood P, Chan O, Dai Y, Thornquist MD, Goodison S, Rosser CJ.

J Transl Med. 2016 Jan 30;14:31. doi: 10.1186/s12967-016-0783-2.

12.

Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature.

Zhang G, Gomes-Giacoia E, Dai Y, Lawton A, Miyake M, Furuya H, Goodison S, Rosser CJ.

Diagn Pathol. 2014 Nov 12;9:200. doi: 10.1186/s13000-014-0200-1.

13.

Cancer progression modeling using static sample data.

Sun Y, Yao J, Nowak NJ, Goodison S.

Genome Biol. 2014 Aug 26;15(8):440. doi: 10.1186/s13059-014-0440-0.

14.

External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.

Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1804-12. doi: 10.1158/1055-9965.EPI-14-0029. Epub 2014 Jun 11.

15.

Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.

Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L, Egan JO, Rhode PR, Parker AS, Chai KX, Wong HC, Rosser CJ.

PLoS One. 2014 Jun 4;9(6):e96705. doi: 10.1371/journal.pone.0096705. eCollection 2014.

16.

Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors.

Zhang G, Miyake M, Lawton A, Goodison S, Rosser CJ.

BMC Cancer. 2014 May 3;14:310. doi: 10.1186/1471-2407-14-310.

17.

Urinary protein biomarker panel for the detection of recurrent bladder cancer.

Rosser CJ, Chang M, Dai Y, Ross S, Mengual L, Alcaraz A, Goodison S.

Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1340-5. doi: 10.1158/1055-9965.EPI-14-0035. Epub 2014 Apr 8.

18.

Simultaneous multi-analyte urinary protein assay for bladder cancer detection.

Rosser CJ, Dai Y, Miyake M, Zhang G, Goodison S.

BMC Biotechnol. 2014 Apr 1;14:24. doi: 10.1186/1472-6750-14-24.

19.

Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway.

Miyake M, Goodison S, Lawton A, Gomes-Giacoia E, Rosser CJ.

Oncogene. 2015 Feb 12;34(7):890-901. doi: 10.1038/onc.2014.2. Epub 2014 Feb 24.

20.

MULTIPLEX URINARY TESTS FOR BLADDER CANCER DIAGNOSIS.

Urquidi V, Rosser CJ, Goodison S.

Eur Med J Urol. 2013;1:70-73.

21.

Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer.

Miyake M, Lawton A, Dai Y, Chang M, Mengual L, Alcaraz A, Goodison S, Rosser CJ.

BMC Cancer. 2014 Feb 13;14:86. doi: 10.1186/1471-2407-14-86.

22.

Deleted in liver cancer-1 (DLC1): an emerging metastasis suppressor gene.

Popescu NC, Goodison S.

Mol Diagn Ther. 2014 Jun;18(3):293-302. doi: 10.1007/s40291-014-0086-3. Review.

23.

PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation.

Giacoia EG, Miyake M, Lawton A, Goodison S, Rosser CJ.

Mol Cancer Res. 2014 Mar;12(3):322-34. doi: 10.1158/1541-7786.MCR-13-0543. Epub 2014 Jan 24.

24.

Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer.

Miyake M, Lawton A, Goodison S, Urquidi V, Rosser CJ.

Pathol Res Pract. 2014 Feb;210(2):74-8. doi: 10.1016/j.prp.2013.08.013. Epub 2013 Oct 28.

PMID:
24252309
25.

Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.

Gomes-Giacoia E, Miyake M, Goodison S, Rosser CJ.

Mol Cancer Ther. 2013 Dec;12(12):2697-708. doi: 10.1158/1535-7163.MCT-13-0500. Epub 2013 Sep 26.

26.

Urinary biomarkers of bladder cancer: an update and future perspectives.

Rosser CJ, Urquidi V, Goodison S.

Biomark Med. 2013 Oct;7(5):779-90. doi: 10.2217/bmm.13.73. Review.

PMID:
24044570
27.

Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: a pre-clinical evaluation.

Sankpal UT, Lee CM, Connelly SF, Kayaleh O, Eslin D, Sutphin R, Goodison S, Adwan L, Zawia NH, Lichtenberger LM, Basha R.

Cell Physiol Biochem. 2013;32(3):675-86. doi: 10.1159/000354471. Epub 2013 Sep 10.

28.

Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection.

Miyake M, Ross S, Lawton A, Chang M, Dai Y, Mengual L, Alcaraz A, Giacoia EG, Goodison S, Rosser CJ.

BMC Urol. 2013 Sep 5;13:42. doi: 10.1186/1471-2490-13-42.

29.

Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions.

Miyake M, Goodison S, Lawton A, Zhang G, Gomes-Giacoia E, Rosser CJ.

J Hematol Oncol. 2013 Sep 3;6:65. doi: 10.1186/1756-8722-6-65.

30.

Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers.

Miyake M, Lawton A, Goodison S, Urquidi V, Gomes-Giacoia E, Zhang G, Ross S, Kim J, Rosser CJ.

BMC Cancer. 2013 Jul 1;13:322. doi: 10.1186/1471-2407-13-322.

31.

Multiplex protein signature for the detection of bladder cancer in voided urine samples.

Rosser CJ, Ross S, Chang M, Dai Y, Mengual L, Zhang G, Kim J, Urquidi V, Alcaraz A, Goodison S.

J Urol. 2013 Dec;190(6):2257-62. doi: 10.1016/j.juro.2013.06.011. Epub 2013 Jun 11.

32.

Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways.

Miyake M, Goodison S, Urquidi V, Gomes Giacoia E, Rosser CJ.

Lab Invest. 2013 Jul;93(7):768-78. doi: 10.1038/labinvest.2013.71. Epub 2013 Jun 3.

33.

Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests.

Goodison S, Rosser CJ, Urquidi V.

Mol Diagn Ther. 2013 Apr;17(2):71-84. doi: 10.1007/s40291-013-0023-x. Review.

34.

Complete Genome Sequence of Mycoplasma hyorhinis Strain SK76.

Goodison S, Urquidi V, Kumar D, Reyes L, Rosser CJ.

Genome Announc. 2013 Jan;1(1). pii: e00101-12. doi: 10.1128/genomeA.00101-12. Epub 2013 Feb 7.

35.

Diagnostic Potential of Urinary <alpha>1-Antitrypsin and Apolipoprotein E in the Detection of Bladder Cancer.

Urquidi V, Goodison S, Rosser CJ.

J Urol. 2013 Jan 12. pii: S0022-5347(13)00051-7. doi: 10.1016/j.juro.2013.01.022. [Epub ahead of print] No abstract available.

PMID:
23321582
36.

A candidate molecular biomarker panel for the detection of bladder cancer.

Urquidi V, Goodison S, Cai Y, Sun Y, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2012 Dec;21(12):2149-58. doi: 10.1158/1055-9965.EPI-12-0428. Epub 2012 Oct 24.

37.

A multi-analyte assay for the non-invasive detection of bladder cancer.

Goodison S, Chang M, Dai Y, Urquidi V, Rosser CJ.

PLoS One. 2012;7(10):e47469. doi: 10.1371/journal.pone.0047469. Epub 2012 Oct 19.

38.

Diagnostic potential of urinary α1-antitrypsin and apolipoprotein E in the detection of bladder cancer.

Urquidi V, Goodison S, Ross S, Chang M, Dai Y, Rosser CJ.

J Urol. 2012 Dec;188(6):2377-83. doi: 10.1016/j.juro.2012.07.094. Epub 2012 Oct 22.

39.

The cancer testis antigen PRAME as a biomarker for solid tumor cancer management.

Goodison S, Urquidi V.

Biomark Med. 2012 Oct;6(5):629-32. doi: 10.2217/bmm.12.65. Review. No abstract available.

PMID:
23075240
40.

Urinary BTA: indicator of bladder cancer or of hematuria.

Miyake M, Goodison S, Rizwani W, Ross S, Bart Grossman H, Rosser CJ.

World J Urol. 2012 Dec;30(6):869-73. doi: 10.1007/s00345-012-0935-9. Epub 2012 Aug 30.

41.

Influencing factors on the NMP-22 urine assay: an experimental model.

Miyake M, Goodison S, Giacoia EG, Rizwani W, Ross S, Rosser CJ.

BMC Urol. 2012 Aug 28;12:23. doi: 10.1186/1471-2490-12-23.

42.

An optimized isolation of biotinylated cell surface proteins reveals novel players in cancer metastasis.

Karhemo PR, Ravela S, Laakso M, Ritamo I, Tatti O, Mäkinen S, Goodison S, Stenman UH, Hölttä E, Hautaniemi S, Valmu L, Lehti K, Laakkonen P.

J Proteomics. 2012 Dec 21;77:87-100. doi: 10.1016/j.jprot.2012.07.009. Epub 2012 Jul 17.

43.

Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis.

Urquidi V, Rosser CJ, Goodison S.

Curr Med Chem. 2012;19(22):3653-63. Review.

44.

CCL18 in a multiplex urine-based assay for the detection of bladder cancer.

Urquidi V, Kim J, Chang M, Dai Y, Rosser CJ, Goodison S.

PLoS One. 2012;7(5):e37797. doi: 10.1371/journal.pone.0037797. Epub 2012 May 21.

45.

IL-8 as a urinary biomarker for the detection of bladder cancer.

Urquidi V, Chang M, Dai Y, Kim J, Wolfson ED, Goodison S, Rosser CJ.

BMC Urol. 2012 May 4;12:12. doi: 10.1186/1471-2490-12-12.

46.

Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection.

Urquidi V, Goodison S, Kim J, Chang M, Dai Y, Rosser CJ.

Urology. 2012 May;79(5):1185.e1-6. doi: 10.1016/j.urology.2012.01.016. Epub 2012 Mar 3.

47.

Production of IL1-beta by ovarian cancer cells induces mesothelial cell beta1-integrin expression facilitating peritoneal dissemination.

Watanabe T, Hashimoto T, Sugino T, Soeda S, Nishiyama H, Morimura Y, Yamada H, Goodison S, Fujimori K.

J Ovarian Res. 2012 Feb 1;5(1):7. doi: 10.1186/1757-2215-5-7.

48.

α2 Integrin-Dependent Suppression of Pancreatic Adenocarcinoma Cell Invasion Involves Ectodomain Regulation of Kallikrein-Related Peptidase-5.

Lee CY, Marzan D, Lin G, Goodison S, Silletti S.

J Oncol. 2011;2011:365651. doi: 10.1155/2011/365651. Epub 2011 Dec 13.

49.

A novel aptamer developed for breast cancer cell internalization.

Zhang K, Sefah K, Tang L, Zhao Z, Zhu G, Ye M, Sun W, Goodison S, Tan W.

ChemMedChem. 2012 Jan 2;7(1):79-84. doi: 10.1002/cmdc.201100457. Epub 2011 Dec 14.

50.

Targeting Sp1 transcription factors in prostate cancer therapy.

Sankpal UT, Goodison S, Abdelrahim M, Basha R.

Med Chem. 2011 Sep;7(5):518-25. Review.

PMID:
22022994

Supplemental Content

Loading ...
Support Center